Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-Outcomes
2025-523123-22-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 38
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and chronic kidney disease (CKD) comparing Orforglipron with Placebo to match (2 arms). Primary endpoint: Time to first occurrence of composite major cardiovascular events endpoint. Planned start May 2026; status: authorised.
02
Drugs
orforglipron
03
Conditions
atherosclerotic diseasechronic kidney disease (CKD)
Beyond the preview
Go deeper on 2025-523123-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523123-22-00.